The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from patients' medical charts (electronic medical records) starting from the initiation of eltrombopag treatment.

Inclusion criteria:

1. Male or female pediatric patients aged ≥2 years and <18 years at the time of initiating eltrombopag and IST treatment.
2. Subjects diagnosed with sAA and treated with eltrombopag in combination with IST as first-line therapy, based on the physician's decision in accordance with locally approved prescribing information at the time of data collection.
3. Subjects whose analytical index date (start date of eltrombopag administration) was at least 6 months prior to the data extraction date.

Exclusion criteria:

None.

Pediatric patients with sAA who initiated eltrombopag and IST treatment in Korea.